News
Lysogene Receives MHRA and Research Ethics Committee Approvals to Initiate the Gene Therapy Clinical Trial in the UK with LYS-GM101 for the Treatment of GM1 Gangliosidosis 150 150 Lysogene

Lysogene Receives MHRA and Research Ethics Committee Approvals to Initiate the Gene Therapy Clinical Trial in the UK with LYS-GM101 for the Treatment of GM1 Gangliosidosis

LYS-GM101 is Lysogene’s second CNS gene therapy program to enter clinic Trial enrollment expected to begin during the first half of 2021 Paris, France — 11 January 2021 at 08:00am — Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announces that it has received MHRA…

Lysogene Reports Positive Biomarker data with LYS-SAF302 150 150 Lysogene

Lysogene Reports Positive Biomarker data with LYS-SAF302

Decrease in heparan sulfate concentration in cerebrospinal fluid Decrease in GM2 and GM3 ganglioside in cerebrospinal fluid Full data to be presented at the WORLDSymposium™ 2021 Paris, France — 28 December 2020 at 08:00am — Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today reports positive…

Lysogene Announces a Change in the Organization of KGA, Minority Shareholder of Lysogene 150 150 Lysogene

Lysogene Announces a Change in the Organization of KGA, Minority Shareholder of Lysogene

Paris, France — 18 December 2020 at 08:00am — Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces a change in the governance and control of KGA, a company co-owned by Karen Aiach and which currently owns approximately 6% of Lysogene’s capital. As part of a…

Lysogene Reports its Cash Position as of 30 September 2020 150 150 Lysogene

Lysogene Reports its Cash Position as of 30 September 2020

Cash and cash equivalents of €22.1 million1 as of 30 September 2020 Paris, France — 19 November 2020 at 08:00am — Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today reports its cash position as of 30 September 2020. As of 30 September 2020, cash and…

Lysogene provides update on the AAVance Clinical Trial Evaluating LYS- SAF302 in Patients with MPS IIIA 150 150 Lysogene

Lysogene provides update on the AAVance Clinical Trial Evaluating LYS- SAF302 in Patients with MPS IIIA

Paris, France — 15 October 2020 at 08:00am — Lysogene (FR0013233475 – LYS), a Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced that a patient has passed away in the AAVance clinical trial (NCT03612869), a global Phase 2/3 gene therapy trial for the treatment of Mucopolysaccharidosis Type IIIA (MPS…

Lysogene Reports First Half 2020 Financial Results and Provides Operational Update 150 150 Lysogene

Lysogene Reports First Half 2020 Financial Results and Provides Operational Update

Cash position of €23.8m as of 30 June 2020 strengthened by a €7.7m capital increase ledby OrbiMed and Sarepta, extending cash runway to Q4 2021

Lysogene: First Half 2020 Business Update 150 150 Lysogene

Lysogene: First Half 2020 Business Update

Cash and cash equivalent of €23.8 million1 as of 30 June 2020 FDA letter on LYS-SAF302 received as planned on July 2, 2020, with no change to expected regulatory timelines Paris, France — 24 July 2020 at 08:00am CEST— Lysogene (FR0013233475 – LYS), a Phase 3 gene therapy platform company targeting central nervous system (CNS)…

Lysogene announces a research collaboration with the Weizmann Institute of Science 150 150 Lysogene

Lysogene announces a research collaboration with the Weizmann Institute of Science

Novel AAV gene therapy approach for neuronopathic Gaucher disease and Parkinson disease with GBA1 mutations Paris, France — 01 July 2020 — Lysogene (FR0013233475 – LYS), a Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced that the company has entered into a collaborative research agreement with Yeda Research and…

LYSOGENE releases the results from June 26, 2020 ordinary annual and extraordinary general meeting 150 150 Lysogene

LYSOGENE releases the results from June 26, 2020 ordinary annual and extraordinary general meeting

Shareholders approved all proposed resolutions Paris, France — 26 June 2020 — Lysogene (FR0013233475-LYS) held its ordinary annual and extraordinary general meeting of shareholders on June 26, 2020, in closed session, which was chaired by Karen Aiach, Chairman of the Board of directors and chief executive officer, without the physical presence of the shareholders. With…

Lysogene announces important updates on AAVance phase 2/3 clinical trial with LYS-SAF302 in MPS IIIA 150 150 Lysogene

Lysogene announces important updates on AAVance phase 2/3 clinical trial with LYS-SAF302 in MPS IIIA

Paris, France — 05 June 2020 at 08:00am CEST— Lysogene (FR0013233475 – LYS), a Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced that, following discussions with the U.S. Food and Drug Administration (FDA), a clinical hold was issued for the clinical trial AAVance (NCT03612869), a global Phase 2/3 clinical…

Lysogene COVID-19 update

Find out More

Lysogene is developing therapies for children with CNS diseases.

Delivering Gene Therapy’s Promise

About Us
Our Science
Meet the Team
Diseases
Resources

Contact Us
Careers
Transparency
Compassionate Use Policy

©2020 Lysogene. All rights reserved.

Cookie Policy
Privacy Policy
Legal Notice

Get In Touch

Don’t hesitate to contact us if you need more help.

    Back to top